Trial · NCT03912532
Results by group188
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 188
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Liver Fibrosis Response After Administration With Aldafermin in Participants With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis | Aldafermin 0.3 mg | 0.24 | Standard Error 0.04 | score on a scale | |
| Liver Fibrosis Response After Administration With Aldafermin in Participants With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis | Aldafermin 1.0 mg | 0.25 | Standard Error 0.04 | score on a scale | |
| Liver Fibrosis Response After Administration With Aldafermin in Participants With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis | Aldafermin 3.0 mg | 0.27 | Standard Error 0.07 | score on a scale | |
| Liver Fibrosis Response After Administration With Aldafermin in Participants With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis | Placebo | 0.23 | Standard Error 0.06 | score on a scale | |
| Number of Participants With Treatment-emergent Adverse Events After Administration With Aldafermin in Participants With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis | Aldafermin 0.3 mg | Any TEAE | 30 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events After Administration With Aldafermin in Participants With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis | Aldafermin 1.0 mg | Any TEAE | 34 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events After Administration With Aldafermin in Participants With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis | Aldafermin 3.0 mg | Any TEAE | 38 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events After Administration With Aldafermin in Participants With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis | Placebo | Any TEAE | 36 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events After Administration With Aldafermin in Participants With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis | Aldafermin 0.3 mg | Any TEAE, Grade 1 | 11 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events After Administration With Aldafermin in Participants With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis | Aldafermin 1.0 mg | Any TEAE, Grade 1 | 12 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events After Administration With Aldafermin in Participants With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis | Aldafermin 3.0 mg | Any TEAE, Grade 1 | 17 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events After Administration With Aldafermin in Participants With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis | Placebo | Any TEAE, Grade 1 | 10 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events After Administration With Aldafermin in Participants With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis | Aldafermin 0.3 mg | Any TEAE, Grade 2 | 16 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events After Administration With Aldafermin in Participants With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis | Aldafermin 1.0 mg | Any TEAE, Grade 2 | 18 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events After Administration With Aldafermin in Participants With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis | Aldafermin 3.0 mg | Any TEAE, Grade 2 | 19 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events After Administration With Aldafermin in Participants With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis | Placebo | Any TEAE, Grade 2 | 24 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events After Administration With Aldafermin in Participants With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis | Aldafermin 0.3 mg | Any TEAE, Grade 3 | 1 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events After Administration With Aldafermin in Participants With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis | Aldafermin 1.0 mg | Any TEAE, Grade 3 | 2 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events After Administration With Aldafermin in Participants With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis | Aldafermin 3.0 mg | Any TEAE, Grade 3 | 2 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events After Administration With Aldafermin in Participants With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis | Placebo | Any TEAE, Grade 3 | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03912532/results